Osteosarcoma (OS) is the most common primary malignant bone
tumor and mainly affects children and adolescents. The OS five-year survival rate remains very low. Thus, novel therapeutic protocols for the treatment of OS are needed. Several approaches targeting deregulated signaling pathways have been proposed. The antitumoral effects of
polyphenols, which are naturally occurring compounds with potent
antioxidant and anti-inflammatory activity, have been investigated in different
tumors.
Gossypol, which is a natural polyphenolic
aldehyde isolated from the seeds of the cotton plant, has been shown to exert antitumoral activity in
leukemia and
lymphoma and in breast, head and neck, colon and
prostate cancers. Therefore, in this study, we evaluated the effect of
AT-101, which is the (-) enantiomer and more active form of
gossypol, on the growth of human and murine OS cells in vitro and in vivo. Several clinical trials employing
AT-101 have been performed, and some clinical trials are ongoing. Our results showed for the first time that
AT-101 significantly inhibits OS cell growth in a dose- and time-dependent manner, inducing apoptosis and
necrosis and partially activating autophagy. Our results demonstrated that
AT-101 inhibits prosurvival signaling pathways depending on Akt,
p38 MAPK and JNK. In addition, treatment with
AT-101 increases the survival of OS-bearing mice. Overall, these results suggest that
AT-101 is a candidate chemo-supportive molecule for the development of novel chemotherapeutic protocols for the treatment of OS.